• Emmaus Life Sciences posted a net loss of $3.3 million for the quarter ended March 31, 2026, widening from $2.3 million a year earlier.
• Net revenues fell 18% to $2 million from the year-ago quarter, on lower U.S. sales tied to competition from ANI Pharmaceuticals’ generic L-Glutamine oral powder launched in mid-2024.
• Other expense climbed 86% to $2.5 million, driven by higher interest expense and a higher change in fair value of conversion feature derivative.
• Cash and cash equivalents totaled $1.1 million as of March 31, 2026, with accumulated deficit of $273.4 million and management citing substantial doubt about ability to continue as a going concern for 12 months from issuance of the financial statements.
• Company highlighted a pending U.S. and Canada Endari license and exclusive distribution deal with NeoImmuneTech, with an Effective Date contingent on regulatory approvals and terminable if not reached by Oct. 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-226362), on May 15, 2026, and is solely responsible for the information contained therein.